KV Channel Antibodies for Pain Research Explorer Kit

A Screening Package of KV Channel Antibodies for Pain Research Economically Priced
  • Lyophilized Powder
  • Antigen Incl.
  • Shipped at Room Temp.
Cat #: AK-385
Sizes: 12 Vials
Last update: 27/11/2018

Alomone Labs is pleased to offer the KV Channel Antibodies for Pain Research Explorer Kit (#AK-385). This Explorer Kit includes KV channel antibodies for pain research with their respective peptide control antigen. An ideal tool for screening purposes.

For research purposes only, not for human use
Compounds
Product NameCat #Size
Anti-KV1.1 (KCNA1) Antibody
APC-009 1 x 50 µl
Anti-KV1.1 (KCNA1) (extracellular) Antibody
APC-161 1 x 50 µl
Anti-KV4.2 Antibody
APC-023 1 x 50 µl
Guinea pig Anti-KV4.2 Antibody
AGP-038 1 x 50 µl
Anti-KCNQ2 Antibody
APC-050 1 x 50 µl
Anti-KCNQ3 Antibody
APC-051 1 x 50 µl
Note A Guinea pig polyclonal antibody (#AGP-038) is included in this Explorer Kit. Please take into account when reacting with a secondary antibody.
Scientific Background
Scientific Background

Voltage gated potassium channel subunits (KV) were found to be related to hyperexcitability of injured nerves and pain transduction The predominant KV1 channels in myelinated nerve fibers comprise of co-assembled KV1.1KV1.2, and KV2.1 that form dendrotoxin (DTX)-sensitive delayed-rectifier channels.  Interestingly, KV1.4 is the sole subunit expressed in small types of fibers such as Aδ and C1.

The trigeminal nerve has a predominant sensory function compared with that of other peripheral nerves such as sciatic nerve because it is predominantly composed of sensory afferents, and only contains a small number of efferent fibers thus demonstrating the neuropathic pain mechanism following a purely sensory nerve injury. Experiments in trigeminal neuropathic/inflammatory pain model indicate that the common activity of the KV channels, such as IA, IK in rats with neuropathic/inflammatory pain, are significantly suppressed compared to those in naïve rats.

Several types of KV channels have been proposed as potential target candidates for pain therapy. It has recently been demonstrated that a selective KCNQ/KV7 channel opener (Retigabine), which mediates M-currents, selectively reduces the activity of axotomized Aδ/C-fibers, but not uninjured axons and human C-fiber axons. In addition Retigabine could attenuate allodynia due to TMJ inflammation in rats2.

References
  1. Rasband, M.N. et al. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 13373.
  2. Takeda, M. et al. (2011) Mol. Pain 7, 5.
Related Products